Tagged with Diabetes

Italy Lilly’s president and general manager for its Italy hub, Huzur Devletsah, explains the company’s broad footprint in the country – where Lilly maintains a large manufacturing site that produces over half of their global insulin output and from which it oversees 28 countries. In addition, she comments on the upcoming…

Saudi Arabia Melvin D’Souza outlines the strategy that Novo Nordisk Saudi Arabia – the country’s market leader in diabetes care, obesity, hemophilia, and growth hormone treatment – is following and analyzes the potential impact of local content enhancement for the Kingdom’s Vision 2030 healthcare transformation plans.   The fact that Novo Nordisk…

Denmark Although Zealand Pharma has been around for 23 years, it has made rapid progress since French national Emmanuel Dulac took the helm as president and CEO in April 2019, with a first new drug application (NDA) and approval, a first in-licensing, and two acquisitions.   Dulac – a veteran of…

Global On the 100th anniversary of the development of insulin, regular PharmaBoardroom contributor Brendan Shaw* examines the shocking global disparities in access to the lifesaving drug, but does not point the finger of blame at the pharmaceutical industry. Instead, Shaw highlights the high barriers of entry that dissuade these companies from…

Denmark Kasper Bødker Mejlvang oversees Novo Nordisk’s operations in its historic home market of Denmark, as well as Iceland. Here, Bødker Mejlvang explains his strategy for steering the Danish affiliate through the COVID-19 pandemic, the evolving access landscape for the company’s next-generation diabetes and obesity treatments, and why Denmark – despite…

Global With advances in technology, an increasing number of stable peptide-based therapeutics are being brought to market today across a wide range of therapeutic areas. Through expert insight, we explain why the peptide field is generating so much excitement, outline some of the most significant recent breakthroughs and big-ticket investments, and…

Denmark Zealand Pharma’s Emmanuel Dulac, fresh from a first US FDA approval for the company’s rescue pen for severe hypoglycaemia in people with diabetes aged 6 years and older, outlines the swift progress that the Danish biotech has made in his two and a half years as CEO. Dulac also highlights…

Saudi Arabia Saudi Arabia has one of the highest rates of diabetes in the world – over 17 percent of the population are diabetic – making the supply of insulin products a matter of significant national interest. To this end, the recent Memorandum of Understanding (MoU) signed between historic US diabetes leader…

Denmark Boehringer Ingelheim’s Nicolas Dumoulin outlines Denmark’s relevance to the German family-owned company, including the strong uptake of its diabetes and COPD medications in the country and its host of research collaborations with local partners.   There is a wealth of knowledge in Denmark, especially in the cardiometabolic area, and a…

Saudi Arabia Having commenced his journey with American giant Lilly in 2008, and after almost eight years working in the company’s Japan organization, mostly on digital marketing, Dimitri Livadas crossed the Pacific Ocean to work in Lilly’s home market and the largest pharma market in the world, the United States, first in…

Singapore Singapore is one of the healthiest countries in Asia with a life expectancy in excess of 82 years buttressed by one of the most robust healthcare apparatuses in the world. “It’s important not to overlook the strengths of this system and just how strong healthcare delivery, affordability and access is…

Saudi Arabia Lilly Saudi Arabia’s Dimitri Livadas shares some of the misconceptions he had before moving to the Kingdom a couple of years ago, highlights the evolution of the Saudi healthcare system with its current focus on digital health, the big opportunities for the Indiana-based company’s diabetes portfolio at a moment when…